This document summarizes information about the top 15 pharmaceutical companies in the world in 2015. It provides sales figures and rankings for the top 5 selling drugs worldwide from 2014. It also discusses how the "patent cliff" has affected drug makers as major drugs lose patent protection. Additionally, it outlines key factors for the US pharmaceutical industry's success and discusses the growing pharmaceutical industry and market in India.

1. THE PHARMA
OUTLOOK 2015
Compiled and Delivered
by,
Mr. Namdeo G. Shinde
Assistant Professor,
Satara College of Pharmacy, Satara (MS) India 415004.
12 August 2015.

2. Johnson and Johnson
Novartis
Roche
Pfizer
Sanofi
Merck
GlaxoSmithKline
Gilead sciences
Teva
Amgen
AbbVie
Eli lilly
Bristol Mayers
Astrazeneka, Bayer
WORLD TOP 15 PHARMACEUTICAL COMPANIES

4. Top brands in the world
RANK
BRAND
NAME
GENERIC
NAME
SALE
2014
COMPANY USE APPROVAL
1 Abilify Aripiprazole +2.23%
Bristol
Mayers
Psychosis 2002
2 Humira adalimumab +3.86% AbbVie
Crohns,
Rhematoid
arthritis
2002
3 Nexium Esmoprazole +0.74% Astrazeneka GI disorder 2000
4 Crestor Rosuvastatin +4.53% Astrazeneka Cholesterol 2002
5 Enbrel Etanercept +1.46% Amgen Rhematoid 1998

9. How Is The Patent Cliff Affecting
The Drug Industry?
Pfizer's Lipitor, an anticholesterol that was the world's top selling
drug for eight years, lost market protection at the end of 2011.
In 2012, its sales ranking dropped to 14th, a nearly 61% decline in
one year from $12.9 billion to $5.1 billion 2011
Bristol Myers and Sanofi's Plavix, a blood thinner, number 2 in sales in
2012 at $9.5 billion, dropped to number 12 the next year, to
$5.2 billion.

11. GLOBAL COUNTRY RANKINGS

13. Coverage and payment policies that value innovative medicines
Strong science based regulatory system
IP rights and its enforcements in US and abroad
Competitive corporate tax rates
Govt. & Private funding of R&D and emerging biopharmaceutical
companies
Favourable technology transfer environment
Strong R&D workforce
Favourable trade policy environment
Key points for favourable business operating
environment in US

16. Established in 1983 by Dilip Shanghvi
Sun Pharmaceuticals operates in more than 150 countries across
the world.
In the year 2014, Sun Pharmaceuticals acquired Ranbaxy
Laboratories Limited and became the largest pharmaceutical
company in India and the fifth largest pharmaceutical company in
the world.
1968, Lupin is one of the fastest growing
 Growth rate more than 20%

17. A January 2014 study, by economists Robert Shapiro and Aparna
Mathur, predicted that
‘India could well become a global centre for innovative
drug development and production, increase the life
expectancy of its people, expand output and
employment, and achieve considerable cost savings in
medical care and government subsidies’ by increasing its
IP protection.
A stronger IP environment will certainly have a
positive impact on the Indian economy and
encourage Foreign Direct Investment
Stronger IP rights:

19. As per 'Pharma Vision 2020', the Government of
India aims to make India a global leader in end to end
drug manufacturing
Manufacturing costs in India is low than US due
to low installation and manufacturing costs
Pharmaceutical exports from India have grown at a
CAGR of 21 % over the last decade
Indian vaccines are exported to 150 countries
Currently, Indian drugs are exported to more than 200 countries in
the world, with the US as the key market.

20. India is home to 10,500 manufacturing units and
over 3,000 pharma companies.
Higher spending on R&D, owing to products patents have made India
a major destination for generic drug manufacturing
India's pharma exports stood at US$ 15 billion in 2013-14
India ranks fourth in terms of the total pharma
market share in the Asia Pacific
Approximately 70 % of the patients in developing countries receive Indian
medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates
Foundation, Doctors Without Borders, the UNCTAD etc

21. Gujarat clocked the highest growth rate in
pharmaceuticals market at 22.4 % during November
2014.
CLINICAL TRIALS
Due to cost advantage India is increasingly becoming a hub for clinical trials.
Due to genetically diverse population and availability of skilled doctors
HEALTH INSURENCE
Penetration of health insurance is expected to cover more than
650 million peoples by 2020.
RSBY, JJBY
‘We want to believe that the Govt. will fulfill its promise’
“MAKE IN INDIA”
‘Make, Develop and Innovate in India’

24. Retail Market